Hims & Hers Health Inc. (HIMS) 今日盘中大涨6.23%，引起了市场的广泛关注。
消息面上，美国FDA近日正式宣布将于7月召开咨询委员会会议，讨论是否允许持牌配制药房重新生产部分此前被限制的肽类药物产品，涵盖7种多肽，涉及减重、伤口愈合及改善失眠等领域。这一监管松绑预期对Hims & Hers意义重大，该公司作为平价减肥药供应商及远程医疗平台，肽类药物限制的放宽将显著扩大其在减重及健康业务领域的可及市场，市场情绪持续受到提振。
Hims & Hers Health Inc. (HIMS) 今日盘中大涨6.23%，引起了市场的广泛关注。
消息面上，美国FDA近日正式宣布将于7月召开咨询委员会会议，讨论是否允许持牌配制药房重新生产部分此前被限制的肽类药物产品，涵盖7种多肽，涉及减重、伤口愈合及改善失眠等领域。这一监管松绑预期对Hims & Hers意义重大，该公司作为平价减肥药供应商及远程医疗平台，肽类药物限制的放宽将显著扩大其在减重及健康业务领域的可及市场，市场情绪持续受到提振。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.